Efficacy and tolerability of rasagiline in daily clinical use - A post-marketing observational study in patients with Parkinson's disease

European Journal of Neurology

Volumn 17, Issue 9, 2010, Pages 1164-1171

  Reichmann, H ^a   Jost, W H ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

combination therapy; monotherapy; Parkinson's disease; quality of life; rasagiline; switch

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RASAGILINE;

AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; CONFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MICTURITION; NAUSEA; PARKINSON DISEASE; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RHINITIS; SIDE EFFECT; SLEEP DISORDER; TREMOR; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA;

AGED; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 77955826792     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.02986.x     Document Type: Article

References (12)

1. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol 2002 59 : 1937 1943.
2. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004 61 : 561 566.
3. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009 24 : 564 573.
4. Olanow CW, Hauser R, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design and baseline characteristics. Mov Disord 2008 23 : 2194 2201.
5. Olanow CW, Rascol O. Early rasagiline treatment slows UPDRS decline in the ADAGIO delayed start study. Ann Neurol 2008 64 : S68.
6. Rascol O, Brooks DJ, Melamed E, et al., for the LARGO Study Group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005 365 : 947 954.
7. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol 2005 62 : 241 248.
8. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005 20 : 1502 1507.
9. Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. Mov Disord 2007 22 : 757 765.
10. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969 21 : 343 354.
11. Fahn S, Elton R, members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In : Fahn S, Marsden CD, Calne DB, Goldstein M eds. Recent Developments in Parkinson's Disease, Vol. II.
12. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997 26 : 353 357.